Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature

Basset, 1998, Langerhans cell histiocytosis research. Past, present, and future, Hematol Oncol Clin North Am, 12, 385, 10.1016/S0889-8588(05)70518-9

Rollins, 2016, Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci, Pediatr Blood Cancer, 63, 1704, 10.1002/pbc.26104

Meyerson, 2010, Recurrent BRAF mutations in Langerhans cell histiocytosis, Blood, 116, 1919, 10.1182/blood-2010-04-279083

Abhyankar, 2014, BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups, J Exp Med, 211, 669, 10.1084/jem.20130977

Moshous, 2016, BRAF mutation correlates with high-risk langerhans cell histiocytosis and increased resistance to first-line therapy, J Clin Oncol, 34, 3023, 10.1200/JCO.2015.65.9508

Gillibert-Yvert, 2017, Circulating cell-free BRAF(V600E) as a biomarker in children with Langerhans cell histiocytosis, Br J Haematol, 178, 457, 10.1111/bjh.14695

Moller, 2014, Potential clinical implications of BRAF mutations in histiocytic proliferations, Oncotarget, 5, 4060, 10.18632/oncotarget.2061

Busser, 2014, Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation, J Am Acad Dermatol, 71, e97, 10.1016/j.jaad.2014.03.038

Martinez-Valle, 2018, Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study, JAMA Oncol, 4, 384, 10.1001/jamaoncol.2017.5029

Zinzani, 2015, Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor, J Natl Compr Canc Netw, 13, 715, 10.6004/jnccn.2015.0086

Donadieu, 2015, Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis, JAMA Oncol, 1, 836, 10.1001/jamaoncol.2015.0736

Hutter, 2017, Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH, Blood Adv, 1, 352, 10.1182/bloodadvances.2016003533

Thomas, 2004, A new clinical score for disease activity in Langerhans cell histiocytosis, Pediatr Blood Cancer, 43, 770, 10.1002/pbc.20160

Mandala, 2017, Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders’ analysis, Eur J Cancer, 79, 176, 10.1016/j.ejca.2017.04.007

Schrappe, 2014, Detection and management of minimal residual disease in acute lymphoblastic leukemia, Hematology Am Soc Hematol Educ Program, 2014, 244, 10.1182/asheducation-2014.1.244